NDA 216986 · Guerbet
Elucirem
Gadopiclenol · Intravenous
NovelPriority reviewCDER novel approval, Sep 21, 2022: To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 21, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
21
6 Phase 3, 5 recruiting
FAERS reports
278
100 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Vueway is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of Vueway in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m 2 ), or Acute kidney injury. Screen...
What it is approved for
From the label in effect Apr 3, 2026.
Vueway ® is indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) Vueway is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) ( 1 )
Mechanism: Gadopiclenol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 20, 2026 Supplement 9 · Efficacy LetterLabelMedication Guide
- Sep 21, 2022 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
7 products under this application
- ELUCIREM · GADOPICLENOL 24.255GM/50ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ELUCIREM · GADOPICLENOL 7.2765GM/15ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ELUCIREM · GADOPICLENOL 3.63825GM/7.5ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ELUCIREM · GADOPICLENOL 48.51GM/100ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ELUCIREM · GADOPICLENOL 14.553GM/30ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ELUCIREM · GADOPICLENOL 4.851GM/10ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ELUCIREM · GADOPICLENOL 1.4553GM/3ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadopiclenol" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)Pivotal-lookingCompleted
GuerbetIndustry
NCT03986138 · 324 participants · Start Aug 27, 2019 · Primary completion Dec 9, 2020
Drug: gadopiclenol; Gadobutrol 1 MMOLE/ML Intravenous Solution · For: Lesion in Body Region
Sites: Birmingham, Alabama; Farmington, Connecticut; Chicago, Illinois · 33 sites in all
- Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular DiseasePivotal-lookingRecruiting
GuerbetIndustry
NCT07348640 · 315 participants (planned) · Start Jul 28, 2026 · Primary completion Dec 31, 2027
Drug: gadopiclenol; Gadoterate meglumine (Dotarem) · For: Steno-occlusive Disease
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 43 sites in all
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)Pivotal-lookingCompleted
GuerbetIndustry
NCT02633501 · 312 participants · Start Jun 2016 · Primary completion Jan 2018
Drug: P03277; Gadobenate dimeglumine · For: CNS Lesion; Blood Brain Barrier Defect
Sites: Chicago, Illinois; Boston, Massachusetts; Farmington Hills, Michigan · 28 sites in all
- Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)Pivotal-lookingCompleted
GuerbetIndustry
NCT03996447 · 260 participants · Start Jun 3, 2019 · Primary completion Sep 11, 2020
Drug: gadopiclenol; Gadobutrol 1Mmol/mL Solution for Injection Vial · For: CNS Lesion; Blood Brain Barrier Defect
Sites: Panorama City, California; Farmington, Connecticut; Chicago, Illinois · 33 sites in all
- Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and ChildrenPivotal-lookingCompleted
GuerbetIndustry
NCT06010173 · 240 participants · Start Jul 21, 2023 · Primary completion May 6, 2025
Drug: Gadopiclenol; Comparator (gadobutrol) · For: Lesion in Body Region; CNS Lesion
Sites: Aichi, Japan; Fukuoka, Japan; Gifu, Japan · 27 sites in all
- Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and HemodynamicsPivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT06406517 · 161 participants · Start Aug 5, 2024 · Primary completion Apr 23, 2026
Drug: Gadopiclenol; Gadobenate dimeglumine · For: Congenital Heart Disease
Sites: San Diego, California
Columbia UniversityAcademic, hospital or other
NCT06226129 · 150 participants (planned) · Start Feb 14, 2024 · Primary completion Feb 1, 2027
Drug: Gadopiclenol · For: Prostate Cancer
Sites: New York, New York
- Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain LesionsPivotal-lookingCompleted
GuerbetIndustry
NCT03603106 · 142 participants · Start Nov 25, 2013 · Primary completion Apr 17, 2015
Drug: P03277; Placebo · For: Healthy Volunteers; Brain Lesion
Sites: Antwerp, Belgium
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria64
- pruritus45
- nausea42
- vomiting38
- rash28
- erythema20
- anaphylactic reaction17
- dyspnoea17
- hypersensitivity16
- dizziness15
- headache12
- paraesthesia11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 12 |
| 2024 | 47 |
| 2025 | 121 |
| 2026 | 98 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Elucirem* (Gadopiclenol*) · HCPCS A9573
2024 spending
$1.2M
Beneficiaries
22,982
25,728 claims
Per beneficiary
$51
2024 ASP limit $4.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $123,883 |
| 2024 | $1,173,443 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.
Loevner LA, Kolumban B, Hutóczki G, et al. · Invest Radiol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C, Csszi T, Piskorski W, et al. · Radiology 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Gadopiclenol in MRI diagnosis: A systematic review of its efficacy and safety.
Durrani A, Farooqui S, Ahmad A, et al. · J Neuroradiol 2026 · Systematic Review
- Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System.
Bendszus M, Roberts D, Kolumban B, et al. · Invest Radiol 2020 · Clinical Trial, Phase II, Multicenter Study
- Pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers.
Eto T, Taoka T, Felices M, et al. · Jpn J Radiol 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
- Relaxivity Performance of Gadopiclenol Versus Gadobenate Dimeglumine In Vitro, and Liver and Brain Imaging: A Randomized Crossover Study.
Heidenreich JF, Tamada D, Rice J, et al. · Invest Radiol 2026 · Randomized Controlled Trial, Comparative Study
Sponsor: Guerbet
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.